Abstract
RNA vaccines are attractive, because they exhibit characteristics of subunit vaccines and live-attenuated vectors, including flexible production and induction of both humoral and cellular immunity. While human proof-of-concept for RNA vaccines is still pending, the nascent field of RNA therapeutics has already attracted substantial industry and government funding as well as record investments of private venture capital. Most recently, the WHO acknowledged messenger RNA (mRNA) as a new therapeutic class. In this chapter, we briefly review key developments in RNA vaccines and outline the contents of this volume of Methods in Molecular Biology.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R (eds) (2009) New generation vaccines, 4th edn. CRC Press, New York
Hilleman MR (1998) A simplified vaccinologists’ vaccinology and the pursuit of a vaccine against AIDS. Vaccine 16(8):778–793
Nakaya HI, Pulendran B (2015) Vaccinology in the era of high-throughput biology. Phil Trans R Soc Lond B Biol Sci 370. pii:20140146. doi:10.1098/rstb.2014.0146
Sadanand S, Suscovich TJ, Alter G (2016) Broadly neutralizing antibodies against HIV: new insights to inform vaccine design. Annu Rev Med 67:185–200. doi:10.1146/annurev-med-091014-090749
Walker CM, Grakoui A (2015) Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? Curr Opin Immunol 35:137–143. doi:10.1016/j.coi.2015.06.010
van der Burg SH, Arens R, Ossendorp F et al (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:219–233. doi:10.1038/nrc.2016.16
Nakaya HI, Hagan T, Duraisingham SS et al (2015) Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity 43:1186–1198. doi:10.1016/j.immuni.2015.11.012
Stern-Ginossar N (2015) Decoding viral infection by ribosome profiling. J Virol 89:6164–6166. doi:10.1128/JVI.02528-14
Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74. doi:10.1126/science.aaa4971
Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24(11):1377–1383
Hondowicz BD, Schwedhelm KV, Kas A et al (2012) Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. PLoS One 7(1):e29949
Pascolo S (2004) Messenger RNA-based vaccines. Expert Opin Biol Ther 4:1285–1294
Pascolo S (2015) The messenger’s great message for vaccination. Expert Rev Vaccines 14:153–156. doi:10.1586/14760584.2015.1000871
Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov 13:759–780. doi:10.1038/nrd4278
Ulmer JB, Mansoura MK, Geall AJ (2015) Vaccines “on demand”: science fiction or a future reality. Expert Opin Drug Discov 10:101–106. doi:10.1517/17460441.2015.996128
Kramps T, Probst J (2013) Messenger RNA-based vaccines: progress, challenges, applications. Wiley Interdiscip Rev RNA 4:737–749. doi:10.1002/wrna.1189
Youn H, Chung J-K (2015) Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy. Expert Opin Biol Ther 15:1337–1348. doi:10.1517/14712598.2015.1057563
Wolff JA, Malone RW, Williams P et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468
Leitner WW, Ying H, Restifo NP (1999) DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18:765–777. doi:10.1016/S0264-410X(99)00271-6
Weide B, Carralot J-P, Reese A et al (2008) Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31(2):180–188
Rittig SM, Haentschel M, Weimer KJ et al (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19(5):990–999
Vallazza B, Petri S, Poleganov MA et al (2015) Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond: Recombinant mRNA technology and its application. Wiley Interdiscip Rev RNA. doi:10.1002/wrna.1288
Van Lint S, Heirman C, Thielemans K, Breckpot K (2013) mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9(2):265–274
Granstein RD, Ding W, Ozawa H (2000) Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 114(4):632–636
Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184(2):465–472
Boczkowski D, Nair S (2010) RNA as performance-enhancers for dendritic cells. Expert Opin Biol Ther 10:563–574. doi:10.1517/14712591003614749
Petsch B, Schnee M, Vogel AB et al (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30(12):1210–1216
Geall AJ, Verma A, Otten GR et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 109(36):14604–14609
Brito LA, Chan M, Shaw CA et al (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. doi:10.1038/mt.2014.133
Dolgin E (2015) Business: The billion-dollar biotech. Nature 522:26–28. doi:10.1038/522026a
Chambers M ChemIDplus - 1613055-09-6 - Nadorameran - Searchable synonyms, formulas, resource links, and other chemical information. http://chem.sis.nlm.nih.gov/chemidplus/rn/1613055-09-6. Accessed 29 Mar 2016
WHO Drug Information Vol. 29, No. 2, 2015 - Proposed International Nonproprietary Names, List 113. http://apps.who.int/medicinedocs/en/m/abstract/Js22000en/. Accessed 29 Mar 2016
Karikó K, Weissman D (2007) Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 10(5):523–532
Schlake T, Thess A, Fotin-Mleczek M, Kallen K-J (2012) Developing mRNA-vaccine technologies. RNA Biol 9:1319–1330. doi:10.4161/rna.22269
Brito LA, Kommareddy S, Maione D et al (2014) Self-amplifying mRNA vaccines. Adv Genet 89:179–233
Ulmer JB, Mason PW, Geall A, Mandl CW (2012) RNA-based vaccines. Vaccine 30(30):4414–4418
Uematsu Y, Vajdy M, Lian Y et al (2012) Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol 19:991–998. doi:10.1128/CVI.00031-12
Nielsen H (2011) RNA. Humana Press, Totowa, NJ
Boisguérin V, Castle JC, Loewer M et al (2014) Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside. Br J Cancer 111:1469–1475. doi:10.1038/bjc.2013.820
Desmet CJ, Ishii KJ (2012) Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 12(7):479–491
Scheel B, Teufel R, Probst J et al (2005) Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35:1557–1566. doi:10.1002/eji.200425656
Rettig L, Haen SP, Bittermann AG et al (2010) Particle size and activation threshold: a new dimension of danger signaling. Blood 115(22):4533–4541
Fotin-Mleczek M, Duchardt KM, Lorenz C et al (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34(1):1–15
Barbalat R, Ewald SE, Mouchess ML, Barton GM (2011) Nucleic acid recognition by the innate immune system. Annu Rev Immunol 29:185–214
Wu J, Chen ZJ (2014) Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 32:461–488. doi:10.1146/annurev-immunol-032713-120156
Kagan JC, Barton GM (2015) Emerging principles governing signal transduction by pattern-recognition receptors. Cold Spring Harb Perspect Biol 7:a016253. doi:10.1101/cshperspect.a016253
Brencicova E, Diebold SS (2013) Nucleic acids and endosomal pattern recognition: how to tell friend from foe? Front Cell Infect Microbiol 3:37. doi:10.3389/fcimb.2013.00037
Barchet W, Wimmenauer V, Schlee M, Hartmann G (2008) Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 20(4):389–395
Van Lint S, Goyvaerts C, Maenhout S et al (2012) Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72(7):1661–1671
Hammerich L, Binder A, Brody JD (2015) In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 9:1966–1981. doi:10.1016/j.molonc.2015.10.016
Schlom J, Hodge JW, Palena C et al (2014) Chapter two - therapeutic cancer vaccines. In: Tew KD, Fisher PB (eds) Advances in cancer research. Academic, New York, pp 67–124
Mogler MA, Kamrud KI (2015) RNA-based viral vectors. Expert Rev Vaccines 14:283–312. doi:10.1586/14760584.2015.979798
Chiocca EA, Rabkin SD (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295–300. doi:10.1158/2326-6066.CIR-14-0015
Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787–796
Phua KKL, Nair SK, Leong KW (2014) Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale 6:7715–7729. doi:10.1039/c4nr01346h
Kreiter S, Selmi A, Diken M et al (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70(22):9031–9040
Ravi AD, Sadhna D, Nagpaal D, Chawla L (2015) Needle free injection technology: a complete insight. Int J Pharm Investig 5:192–199. doi:10.4103/2230-973X.167662
Foged C (2016) Thermostable subunit vaccines for pulmonary delivery: how close are we? Curr Pharm Des 22(17):2561–2576
Etschel JK, Hückelhoven AG, Hofmann C et al (2012) HIV-1 mRNA electroporation of PBMC: a simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients. J Immunol Methods 380:40–55. doi:10.1016/j.jim.2012.03.005
Van Camp K, Cools N, Stein B et al (2010) Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes. J Immunol Methods 354:1–10. doi:10.1016/j.jim.2010.01.009
Cools N, Van Camp K, Van Tendeloo V, Berneman Z (2013) mRNA electroporation as a tool for immunomonitoring. Methods Mol Biol 969:293–303
Scully IL, Swanson K, Green L et al (2015) Anti-infective vaccination in the 21st century — new horizons for personal and public health. Curr Opin Microbiol 27:96–102. doi:10.1016/j.mib.2015.07.006
Lopalco PL, DeStefano F (2015) The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine 33:1541–1548. doi:10.1016/j.vaccine.2014.10.047
Goetz KB, Pfleiderer M, Schneider CK (2010) First-in-human clinical trials with vaccines—what regulators want. Nat Biotechnol 28:910–916. doi:10.1038/nbt0910-910
Rabinovich PM (2013) Synthetic messenger RNA and cell metabolism modulation: methods and protocols, 2013th edn. Humana Press, New York
Johansson DX, Ljungberg K, Kakoulidou M, Liljeström P (2012) Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One 7:e29732. doi:10.1371/journal.pone.0029732
Cu Y, Broderick KE, Banerjee K et al (2013) Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ. Vaccines 1:367–383. doi:10.3390/vaccines1030367
Broderick KE, Humeau LM (2015) Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev Vaccines 14(2):195–204. doi:10.1586/14760584.2015.990890
Britten CM, Singh-Jasuja H, Flamion B et al (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31:880–882. doi:10.1038/nbt.2708
Acknowledgments
We thank colleagues in the field for continuing discussions. We also thank Dr. Michel Pairet and Dr. Holger Gellermann of Boehringer Ingelheim for support.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Kramps, T., Elbers, K. (2017). Introduction to RNA Vaccines. In: Kramps, T., Elbers, K. (eds) RNA Vaccines. Methods in Molecular Biology, vol 1499. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6481-9_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6481-9_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6479-6
Online ISBN: 978-1-4939-6481-9
eBook Packages: Springer Protocols